Is Alzamend Neuro Stock a Good Investment?
Alzamend Neuro Investment Advice | ALZN |
- Examine Alzamend Neuro's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Alzamend Neuro's leadership team and their track record. Good management can help Alzamend Neuro navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Alzamend Neuro's business and its evolving consumer preferences.
- Compare Alzamend Neuro's performance and market position to its competitors. Analyze how Alzamend Neuro is positioned in terms of product offerings, innovation, and market share.
- Check if Alzamend Neuro pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Alzamend Neuro's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Alzamend Neuro stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Alzamend Neuro is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Alzamend Neuro Stock
Researching Alzamend Neuro's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 142.87. Alzamend Neuro had not issued any dividends in recent years. The entity had 1:10 split on the 16th of July 2024.
To determine if Alzamend Neuro is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Alzamend Neuro's research are outlined below:
| Alzamend Neuro generated a negative expected return over the last 90 days | |
| Alzamend Neuro may become a speculative penny stock | |
| Alzamend Neuro has high historical volatility and very poor performance | |
| Alzamend Neuro has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (9.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alzamend Neuro currently holds about 11.53 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Alzamend Neuro has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Alzamend Neuro Announces Full Data Set from its Nonclinical Study Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice |
Alzamend Neuro Quarterly Liabilities And Stockholders Equity |
|
Alzamend Neuro uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Alzamend Neuro. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Alzamend Neuro's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Alzamend Neuro's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Alzamend Neuro's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-07-27 | 2023-04-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2022-12-12 | 2022-10-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2022-07-19 | 2022-04-30 | -0.03 | -0.04 | -0.01 | 33 | ||
2022-03-15 | 2022-01-31 | -0.02 | -0.03 | -0.01 | 50 | ||
2023-03-15 | 2023-01-31 | -0.04 | -0.06 | -0.02 | 50 | ||
2021-12-13 | 2021-10-31 | -0.02 | -0.04 | -0.02 | 100 | ||
2022-09-13 | 2022-07-31 | -0.07 | -0.03 | 0.04 | 57 | ||
2024-03-25 | 2024-01-31 | -0.32 | -0.38 | -0.06 | 18 |
Know Alzamend Neuro's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alzamend Neuro is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alzamend Neuro backward and forwards among themselves. Alzamend Neuro's institutional investor refers to the entity that pools money to purchase Alzamend Neuro's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bb&t Corp. | 2024-09-30 | 15.5 K | Parallel Advisors, Llc | 2024-06-30 | 33.0 | Harbor Investment Advisory, Llc | 2024-09-30 | 20.0 | Rfg Advisory Group, Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 |
Alzamend Neuro's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.86 M.Market Cap |
|
Alzamend Neuro's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (15.75) | (14.96) | |
| Return On Capital Employed | 3.83 | 3.64 | |
| Return On Assets | (15.75) | (14.96) | |
| Return On Equity | 3.83 | 3.64 |
Determining Alzamend Neuro's profitability involves analyzing its financial statements and using various financial metrics to determine if Alzamend Neuro is a good buy. For example, gross profit margin measures Alzamend Neuro's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Alzamend Neuro's profitability and make more informed investment decisions.
Evaluate Alzamend Neuro's management efficiency
Alzamend Neuro has return on total asset (ROA) of (2.1447) % which means that it has lost $2.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (44.0831) %, meaning that it created substantial loss on money invested by shareholders. Alzamend Neuro's management efficiency ratios could be used to measure how well Alzamend Neuro manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to grow to -14.96. In addition to that, Return On Capital Employed is likely to drop to 3.64. As of the 23rd of November 2024, Debt To Assets is likely to grow to 0.95, while Net Tangible Assets are likely to drop about 3.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (3.84) | (3.65) | |
| Tangible Book Value Per Share | (3.84) | (3.65) | |
| Enterprise Value Over EBITDA | (0.48) | (0.45) | |
| Price Book Value Ratio | (1.85) | (1.95) | |
| Enterprise Value Multiple | (0.48) | (0.45) | |
| Price Fair Value | (1.85) | (1.95) | |
| Enterprise Value | 865.6 M | 702.2 M |
Evaluating the management effectiveness of Alzamend Neuro allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Alzamend Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta (0.04) |
Basic technical analysis of Alzamend Stock
As of the 23rd of November, Alzamend Neuro shows the Standard Deviation of 4.06, mean deviation of 3.22, and Risk Adjusted Performance of (0.25). Alzamend Neuro technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Alzamend Neuro's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alzamend Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alzamend Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alzamend Neuro insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alzamend Neuro's Outstanding Corporate Bonds
Alzamend Neuro issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alzamend Neuro uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alzamend bonds can be classified according to their maturity, which is the date when Alzamend Neuro has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Alzamend Neuro's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Alzamend Neuro's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.25) | |||
| Market Risk Adjusted Performance | 3.06 | |||
| Mean Deviation | 3.22 | |||
| Coefficient Of Variation | (301.69) | |||
| Standard Deviation | 4.06 | |||
| Variance | 16.5 | |||
| Information Ratio | (0.36) | |||
| Jensen Alpha | (1.30) | |||
| Total Risk Alpha | (2.00) | |||
| Treynor Ratio | 3.05 | |||
| Maximum Drawdown | 19.81 | |||
| Value At Risk | (9.14) | |||
| Potential Upside | 3.7 | |||
| Skewness | (0.57) | |||
| Kurtosis | 0.053 |
| Risk Adjusted Performance | (0.25) | |||
| Market Risk Adjusted Performance | 3.06 | |||
| Mean Deviation | 3.22 | |||
| Coefficient Of Variation | (301.69) | |||
| Standard Deviation | 4.06 | |||
| Variance | 16.5 | |||
| Information Ratio | (0.36) | |||
| Jensen Alpha | (1.30) | |||
| Total Risk Alpha | (2.00) | |||
| Treynor Ratio | 3.05 | |||
| Maximum Drawdown | 19.81 | |||
| Value At Risk | (9.14) | |||
| Potential Upside | 3.7 | |||
| Skewness | (0.57) | |||
| Kurtosis | 0.053 |
Consider Alzamend Neuro's intraday indicators
Alzamend Neuro intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alzamend Neuro stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Alzamend Neuro time-series forecasting models is one of many Alzamend Neuro's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alzamend Neuro's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Alzamend Stock media impact
Far too much social signal, news, headlines, and media speculation about Alzamend Neuro that are available to investors today. That information is available publicly through Alzamend media outlets and privately through word of mouth or via Alzamend internal channels. However, regardless of the origin, that massive amount of Alzamend data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alzamend Neuro news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alzamend Neuro relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alzamend Neuro's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alzamend Neuro alpha.
Alzamend Neuro Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Alzamend Neuro can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alzamend Neuro Corporate Management
| Henry Esq | General VP | Profile | |
| Kenneth CPA | Senior Finance | Profile | |
| David Katzoff | Chief Officer | Profile | |
| Stephan Jackman | CEO Director | Profile |
Already Invested in Alzamend Neuro?
The danger of trading Alzamend Neuro is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alzamend Neuro is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alzamend Neuro. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alzamend Neuro is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (142.87) | Return On Assets (2.14) | Return On Equity (44.08) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Alzamend Neuro's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.